Shares of Synthetic Biologics Inc (NYSEMKT:SYN) have received an average recommendation of “Buy” from the nine ratings firms that are presently covering the company. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $5.22.

SYN has been the topic of a number of research reports. Zacks Investment Research downgraded shares of Synthetic Biologics from a “hold” rating to a “sell” rating in a report on Tuesday, November 1st. FBR & Co reaffirmed a “buy” rating on shares of Synthetic Biologics in a research note on Friday, August 5th. Griffin Securities set a $5.80 price target on shares of Synthetic Biologics and gave the stock a “buy” rating in a research note on Wednesday, August 31st. Finally, BTIG Research assumed coverage on shares of Synthetic Biologics in a research note on Thursday, August 25th. They set a “buy” rating and a $5.00 price target for the company.

A hedge fund recently raised its stake in Synthetic Biologics stock. UBS Group AG raised its stake in shares of Synthetic Biologics Inc (NYSEMKT:SYN) by 378.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 288,367 shares of the company’s stock after buying an additional 228,037 shares during the period. UBS Group AG owned about 0.32% of Synthetic Biologics worth $680,000 as of its most recent filing with the SEC.

Synthetic Biologics (NYSEMKT:SYN) traded down 1.141% during trading on Monday, reaching $0.875. 1,140,545 shares of the company were exchanged. Synthetic Biologics has a 1-year low of $0.85 and a 1-year high of $3.09. The company’s 50-day moving average price is $1.45 and its 200-day moving average price is $1.73. The stock’s market capitalization is $80.65 million.

Synthetic Biologics (NYSEMKT:SYN) last posted its earnings results on Tuesday, November 1st. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. On average, equities analysts forecast that Synthetic Biologics will post ($0.35) EPS for the current year.

About Synthetic Biologics

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Stock Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related stocks with our FREE daily email newsletter.